Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$15.24 +2.8%	$10.89	$6.38 ▼ $16.66	$1.48B	1.47	1.20 million shs	1.55 million shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CVAC CureVac	$5.44 +0.4%	$5.44	$2.37 ▼ $5.72	$1.22B	2.53	704,959 shs	353,942 shs
RCKT Rocket Pharmaceuticals	$3.64 -2.4%	$2.99	$2.19 ▼ $22.01	$392.77M	0.65	5.51 million shs	7.41 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	0.00%	+11.32%	+35.47%	+66.92%	-6.39%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	-1.33%
CVAC CureVac	0.00%	-0.73%	0.00%	+33.01%	+63.86%
RCKT Rocket Pharmaceuticals	0.00%	+19.34%	+13.40%	-41.95%	-81.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.7013 of 5 stars	3.6	3.0	0.0	0.0	2.0	1.7	0.6
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	4.6442 of 5 stars	4.1	5.0	0.0	4.9	1.6	0.0	1.3
RCKT Rocket Pharmaceuticals	4.8779 of 5 stars	4.2	4.0	0.0	4.7	2.9	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.14	Buy	$19.67	29.05% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CVAC CureVac	2.20	Hold	$6.83	25.61% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$16.73	359.71% Upside

Current Analyst Ratings Breakdown

Latest RCKT, AVDL, CVAC, and CALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $20.00
8/20/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $10.00
8/20/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00
8/11/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
8/8/2025	AVDL Avadel Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	AVDL Avadel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $24.00
8/8/2025	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $8.00
7/25/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
7/25/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$9.00 ➝ $4.00
7/24/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $12.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	8.75	N/A	N/A	$0.93 per share	16.39
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CVAC CureVac	$579.18M	2.11	$0.87 per share	6.23	$2.97 per share	1.83
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$3.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.03	N/A	254.00	N/A	-1.32%	-3.73%	-1.73%	11/11/2025 (Estimated)
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CVAC CureVac	$175.50M	$0.96	5.67	N/A	N/A	38.21%	29.57%	25.41%	11/11/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.51	N/A	N/A	N/A	N/A	-65.11%	-55.99%	11/6/2025 (Estimated)

Latest RCKT, AVDL, CVAC, and CALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	CVAC CureVac	-$0.15	-$0.30	-$0.15	-$0.30	$4.27 million	$1.41 million
8/7/2025	Q2 2025	AVDL Avadel Pharmaceuticals	$0.02	$0.10	+$0.08	$0.10	$60.28 million	$68.13 million
8/7/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	-$0.59	-$0.02	-$0.62	$4.36 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.79	2.38
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CVAC CureVac	0.05	6.17	7.64
RCKT Rocket Pharmaceuticals	0.05	6.39	6.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
CALT Calliditas Therapeutics AB (publ)	2.83%
CVAC CureVac	17.26%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
CALT Calliditas Therapeutics AB (publ)	2.20%
CVAC CureVac	2.15%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	97.10 million	92.05 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
CVAC CureVac	880	224.34 million	219.52 million	Optionable
RCKT Rocket Pharmaceuticals	240	107.90 million	81.19 million	Optionable

RCKT, AVDL, CVAC, and CALT Headlines

Recent News About These Companies

Q3 EPS Estimate for Rocket Pharmaceuticals Cut by Analyst

August 23 at 3:33 AM | americanbankingnews.com

EMA says Rocket Pharmaceuticals withdraws MA application for Fanskya

August 22 at 12:11 AM | msn.com

Rocket Pharmaceuticals: Good News As Clinical Hold Lifted - But Challenges Remain

August 22 at 4:07 AM | seekingalpha.com

Rocket Pharmaceuticals (RCKT) Receives a Sell from Goldman Sachs

August 22 at 4:07 AM | theglobeandmail.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to Buy at Bank of America

August 22 at 2:22 AM | americanbankingnews.com

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

August 21 at 12:15 PM | zacks.com

Rocket Pharmaceuticals' (RCKT) "Buy" Rating Reaffirmed at Chardan Capital

August 21 at 3:59 AM | americanbankingnews.com

Rocket Pharmaceuticals announces clinical hold lifted on RP-A501 trial

August 20, 2025 | msn.com

John Militello Sells 7,043 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock

August 20, 2025 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider Sells $33,706.22 in Stock

August 20, 2025 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Martin Wilson Sells 12,109 Shares

August 20, 2025 | marketbeat.com

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

August 20, 2025 | barrons.com

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

August 20, 2025 | benzinga.com

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

August 20, 2025 | reuters.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider John Militello Sells 7,043 Shares

August 19, 2025 | insidertrades.com

Jefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains ‘Hold’ Rating

August 19, 2025 | insidermonkey.com

Rocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform

August 18, 2025 | msn.com

What is Chardan Capital's Forecast for RCKT FY2025 Earnings?

August 16, 2025 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $16.40 Consensus Price Target from Analysts

August 14, 2025 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $11.00 at Chardan Capital

August 13, 2025 | americanbankingnews.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact Levi & Korsinsky

August 12, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT, AVDL, CVAC, and CALT Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$15.24 +0.42 (+2.83%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.26 +0.02 (+0.12%)

As of 08/22/2025 07:57 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 08/22/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

CureVac NASDAQ:CVAC

$5.44 +0.02 (+0.37%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.43 -0.01 (-0.18%)

As of 08/22/2025 05:32 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.64 -0.09 (-2.41%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.66 +0.01 (+0.41%)

As of 08/22/2025 07:59 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time